or
forgot password

Pilot Study of Diffusion MRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B Cell Lymphoma


N/A
18 Years
N/A
Open (Enrolling)
Both
Diffuse Large B Cell Lymphoma

Thank you

Trial Information

Pilot Study of Diffusion MRI as a Tool for Early Evaluation of Tumor Response in Diffuse Large B Cell Lymphoma


Different types of functional imaging are under investigation as a tool to predict response
to treatment, as imaging soon after starting therapy might be able to better define the
likelihood of response. Functional imaging refers to scans that measure characteristics
other than size and shape (anatomic imaging), as measured by CT scans. We are interested in
evaluating the potential value of diffusion Magnetic Resonance Imaging (dMRI), which in some
settings can be used very early in treatment in predicting patients' response to treatment.

Diffusion MRI (dMRI) detects changes in cell structure, and has the potential to detect and
measure cell changes that occur in response to treatment. Several groups are investigating
the use of dMRI to monitor treatment responses. This strategy has been most frequently
explored in humans in patients with brain tumors, where dMRI has been demonstrated to
predict response to treatment early after starting treatment. A few studies have looked at
response in other cancers. These studies showed early changes in patients who later
responded to treatment, with changes seen within one to 2 weeks.

Although diffusion MRI has been shown to be useful in several cancer types, it has not been
explored in the evaluation of lymphoma. This pilot study will evaluate the imaging
characteristics of DLBCL by dMRI prior to treatment and 7 days after initial chemotherapy in
order to explore whether dMRI is useful in evaluating the response of lymphoma to
chemotherapy.


Inclusion Criteria:



- Patients with a new diagnosis of CD20+ diffuse large B cell lymphoma (LBCL) of any
stage, including subtypes mediastinal large B cell, centroblastic, immunoblastic, T
cell rich B cell and anaplastic B cell lymphoma, who will receive standard R/CHOP as
first line chemotherapy will be included.

- Patients must be age 18 or older.

- No selection will be made on the basis of gender, race or ethnicity.

Exclusion Criteria:

- Patients will be excluded if the diagnosis of diffuse large B cell lymphoma cannot be
confirmed.

- Patients receiving treatment other than R/CHOP or R/CHOP followed by radiotherapy or
who have previously been treated for DLBCL will be excluded. - Patients with HIV
infection will also be excluded. No selection will be made based on other medical
problems or laboratory values, except as they affect the patient's eligibility to
receive standard R/CHOP chemotherapy as determined by the treating physician.

- Patients who have magnetic metal implants or fragments in their body that are
incompatible with MRI will be excluded.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To assess whether changes in the apparent diffusion coefficient (ADC) during the early phase of chemotherapy are detectable in lymphoma

Outcome Time Frame:

2 years

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

UMCC 2006.063

NCT ID:

NCT00645359

Start Date:

November 2006

Completion Date:

June 2016

Related Keywords:

  • Diffuse Large B Cell Lymphoma
  • dMRI
  • diffusion MRI
  • Diffuse large B-cell lymphoma
  • DLBCL
  • Lymphoma
  • Lymphoma, B-Cell
  • Lymphoma, Large B-Cell, Diffuse

Name

Location
University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan  48109-0752